BOSTON – Gene therapies have remained a tantalizing promise ever since the early 1990s, said Steve Bagshaw, CEO of Fujifilm Diosynth Biotechnologies, who was moderating a BIO 2018 panel on this exciting area. Now thanks to scientific advances, several product approvals, and significant business development and investments, expectations are once again high that the field has finally reached prime time and is ready to transform 21st century medicine. Read More
